Frequently Asked Questions About 2526.HK

What does Hangzhou Diagens Biotechnology Co., Ltd. do?

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) operates in the Medical - Devices industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 2526.HK's market cap?

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) has a market capitalization of approximately $27.32 billion, as of July 21, 2026, based on the most recent share price and shares outstanding.

Does 2526.HK pay a dividend?

No — Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 2526.HK profitable?

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

2526.HK (Hangzhou Diagens Biotechnology Co., Ltd.) is a recent IPO.

It began trading on March 29, 2026, giving it under six months of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.

2526.HK

Hangzhou Diagens Biotechnology Co., Ltd.

HKSE·Medical, Devices · Healthcare

HK$307.40HK$36.80+13.60%

Market capHK$27.32B·Jul 21 8:08 AM UTC

Price Chart

HK$307.40+HK$36.80 (+13.60%)today

+46.66%

Select date range

FromTo

Mar 30, 2026Mar 30, 2026 → Jul 21, 2026· 4 moJul 21, 2026

Key Metrics

2526.HK does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateJun 18

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

Income Statement Flow

PRO

See exactly how 2526.HK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 2526.HK and 80,000+ other tickers.

About Hangzhou Diagens Biotechnology Co., Ltd.

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company's products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image…

CEO: Ning Song
Sector: Healthcare
Industry: Medical - Devices
Exchange: HKSE
Employees: 166
Website: www.diagens.com

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 2526.HK

What does Hangzhou Diagens Biotechnology Co., Ltd. do?: Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) operates in the Medical - Devices industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 2526.HK's market cap?: Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) has a market capitalization of approximately $27.32 billion, as of July 21, 2026, based on the most recent share price and shares outstanding.
Does 2526.HK pay a dividend?: No — Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 2526.HK profitable?: Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.